GleamWall
中文EN

SCTX Scribe Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1853921 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets33.4%
Debt / equity0.00x
Current ratio4.72x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue$1.64M$1.92M—$20.11M$4.90M—
R&D expense$8.26M$8.82M—$14.42M$13.88M—
SG&A expense$4.24M$2.49M—$3.53M$2.64M—
Operating income-$10.86M-$9.39M—$2.16M-$11.63M—
Interest expense$0$276,000—$598,000$598,000—
Pretax income-$9.63M-$6.26M—$1.80M-$10.62M—
Income tax$231,000$212,000—$324,000-$712,000—
Net income-$9.86M-$6.48M-$17.35M$1.47M-$9.90M-$3.42M
EBITDA-$10.26M-$8.79M—$2.86M-$10.93M—
EPS (basic)-0.68-2.62—0.00-4.08—
EPS (diluted)-0.68-2.62—0.00-4.08—
Weighted avg. shares (diluted)14.50M2.48M—2.43M2.43M—
Balance sheet
Cash & equivalents$172.05M$35.59M—$9.88M$16.66M—
Short-term investments$2.18M$7.42M————
Current assets$178.89M$45.10M————
PP&E, net$5.15M$5.75M————
Total assets$187.93M$57.93M————
Current liabilities$37.93M$78.70M————
Total liabilities$62.76M$102.42M————
Shareholders' equity$125.17M-$164.85M-$158.74M-$134.16M-$137.88M-$128.67M
Shares outstanding18.94M2.49M————
Cash flow statement
Operating cash flow-$11.25M——-$11.29M——
Capital expenditure$13,000——$325,000——
Free cash flow-$11.26M——-$11.62M——
Investing cash flow$5.18M——$4.52M——
Financing cash flow$142.53M——$0——
Depreciation & amortization$600,000$600,000—$700,000$700,000—
Stock-based compensation$1.22M$227,000—$2.23M$676,000—

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.